AI is reshaping clinical research faster than any technology before it; but for sponsors and CROs, adoption without GxP-grade governance, validation, and human oversight isn't a strategy. It's a risk.
Philip Raeth
Advertisement
Philip Raeth is Managing Director at Palleos.
Articles by Philip Raeth
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
FDA Releases Transparency Roadmap Outlining Disclosure Priorities Across Drug Development and Regulatory Review
2
FDA Seeks Public Input on Early-Phase Clinical Trial Design for Ibogaine
3
Beyond the Molecule: Why Radiopharmaceutical Trials Require a New Operating Model
4
Mixed Outsourcing Models Are Spreading. Is Sponsor Oversight Keeping Up?
5